Ji D, Luo Y, Wang J, Chen S, et al. CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis. BMC Cancer 2023;23:805.
PMID: 37644396